These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 25483141)

  • 1. Development of urinary pseudotargeted LC-MS-based metabolomics method and its application in hepatocellular carcinoma biomarker discovery.
    Shao Y; Zhu B; Zheng R; Zhao X; Yin P; Lu X; Jiao B; Xu G; Yao Z
    J Proteome Res; 2015 Feb; 14(2):906-16. PubMed ID: 25483141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudotargeted metabolomics method and its application in serum biomarker discovery for hepatocellular carcinoma based on ultra high-performance liquid chromatography/triple quadrupole mass spectrometry.
    Chen S; Kong H; Lu X; Li Y; Yin P; Zeng Z; Xu G
    Anal Chem; 2013 Sep; 85(17):8326-33. PubMed ID: 23889541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.
    Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW
    J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry.
    Wang B; Chen D; Chen Y; Hu Z; Cao M; Xie Q; Chen Y; Xu J; Zheng S; Li L
    J Proteome Res; 2012 Feb; 11(2):1217-27. PubMed ID: 22200553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of urinary steroid hormone disorders: difference between hepatocellular carcinoma in early stage and cirrhosis.
    Dai W; Yin P; Chen P; Kong H; Luo P; Xu Z; Lu X; Xu G
    Anal Bioanal Chem; 2014 Jul; 406(18):4325-35. PubMed ID: 24817358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
    Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
    Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
    Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
    Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple reaction monitoring-ion pair finder: a systematic approach to transform nontargeted mode to pseudotargeted mode for metabolomics study based on liquid chromatography-mass spectrometry.
    Luo P; Dai W; Yin P; Zeng Z; Kong H; Zhou L; Wang X; Chen S; Lu X; Xu G
    Anal Chem; 2015; 87(10):5050-5. PubMed ID: 25884293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromatographic determination of some biomarkers of liver cirrhosis and hepatocellular carcinoma in Egyptian patients.
    Osman D; Ali O; Obada M; El-Mezayen H; El-Said H
    Biomed Chromatogr; 2017 Jun; 31(6):. PubMed ID: 27862090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases.
    Zhou L; Wang Q; Yin P; Xing W; Wu Z; Chen S; Lu X; Zhang Y; Lin X; Xu G
    Anal Bioanal Chem; 2012 Apr; 403(1):203-13. PubMed ID: 22349331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An improved pseudotargeted metabolomics approach using multiple ion monitoring with time-staggered ion lists based on ultra-high performance liquid chromatography/quadrupole time-of-flight mass spectrometry.
    Wang Y; Liu F; Li P; He C; Wang R; Su H; Wan JB
    Anal Chim Acta; 2016 Jul; 927():82-8. PubMed ID: 27237840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry.
    Wu H; Xue R; Dong L; Liu T; Deng C; Zeng H; Shen X
    Anal Chim Acta; 2009 Aug; 648(1):98-104. PubMed ID: 19616694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry.
    Yin P; Wan D; Zhao C; Chen J; Zhao X; Wang W; Lu X; Yang S; Gu J; Xu G
    Mol Biosyst; 2009 Aug; 5(8):868-76. PubMed ID: 19603122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics.
    Huang Q; Tan Y; Yin P; Ye G; Gao P; Lu X; Wang H; Xu G
    Cancer Res; 2013 Aug; 73(16):4992-5002. PubMed ID: 23824744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolomics study of hepatocellular carcinoma: discovery and validation of serum potential biomarkers by using capillary electrophoresis-mass spectrometry.
    Zeng J; Yin P; Tan Y; Dong L; Hu C; Huang Q; Lu X; Wang H; Xu G
    J Proteome Res; 2014 Jul; 13(7):3420-31. PubMed ID: 24853826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a universal metabolome-standard method for long-term LC-MS metabolome profiling and its application for bladder cancer urine-metabolite-biomarker discovery.
    Peng J; Chen YT; Chen CL; Li L
    Anal Chem; 2014 Jul; 86(13):6540-7. PubMed ID: 24877652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel analysis method for biomarker identification based on horizontal relationship: identifying potential biomarkers from large-scale hepatocellular carcinoma metabolomics data.
    Su B; Luo P; Yang Z; Yu P; Li Z; Yin P; Zhou L; Fan J; Huang X; Lin X; Qiao Y; Xu G
    Anal Bioanal Chem; 2019 Sep; 411(24):6377-6386. PubMed ID: 31384984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.
    Chen T; Xie G; Wang X; Fan J; Qiu Y; Zheng X; Qi X; Cao Y; Su M; Wang X; Xu LX; Yen Y; Liu P; Jia W
    Mol Cell Proteomics; 2011 Jul; 10(7):M110.004945. PubMed ID: 21518826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Untargeted metabolomics of blood plasma samples of patients with hepatocellular carcinoma.
    Böhmová A; Mikoška M; Syslová K; Šindelářová D; Hříbek P; Urbánek P; Setnička V
    J Pharm Biomed Anal; 2024 Sep; 248():116263. PubMed ID: 38852296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery.
    Di Poto C; Ferrarini A; Zhao Y; Varghese RS; Tu C; Zuo Y; Wang M; Nezami Ranjbar MR; Luo Y; Zhang C; Desai CS; Shetty K; Tadesse MG; Ressom HW
    Cancer Epidemiol Biomarkers Prev; 2017 May; 26(5):675-683. PubMed ID: 27913395
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.